AOD9604 vs retatrutide compared: how these two weight-loss peptides differ in mechanism, dosing, trial results, side effects, and FDA approval status.
AOD9604 and retatrutide are two very different compounds that get compared because both are researched for weight loss. AOD9604 is a synthetic fragment of human growth hormone that acts directly on fat cells, while retatrutide is an investigational drug that switches on three hormone receptors at once. Neither is FDA-approved for human use, and the clinical evidence behind them is not remotely equal.
What Is AOD9604?
AOD9604 (also written AOD-9604 or hGH 176-191) is a shortened piece of the human growth hormone molecule. Scientists engineered it to preserve growth hormone's fat-burning activity while removing the parts that raise IGF-1 and disrupt blood sugar.
Lab research suggests the peptide encourages lipolysis, the breakdown of stored fat, and discourages lipogenesis, the creation of new fat. Australian researchers took it into Phase 2 human trials for obesity in the 2000s, but the weight loss it produced was modest and development quietly stalled.
Because no approved product exists, AOD9604 is sold online as a research chemical. Grey-market protocols commonly cited online call for 250 to 500 micrograms injected under the skin once per day, though no regulatory body has reviewed that dose for safety or effectiveness. AOD9604 is also named on the World Anti-Doping Agency's S0 list of non-approved substances.
What Is Retatrutide?
Retatrutide (development code LY3437943) is an investigational drug from Eli Lilly that activates three receptors at once: GLP-1, GIP, and glucagon. That triple mechanism sets it apart from every approved weight-loss medication on the US market.
It is given as a once-weekly subcutaneous injection. In trials, participants started low and stepped up over several months to a maximum of 12 mg per week.
The Phase 2 trial published in the New England Journal of Medicine in 2023 enrolled 338 adults with obesity. At 48 weeks, participants on the 12 mg dose lost an average of about 24% of their body weight, roughly 58 pounds for someone starting at 240 pounds. Few obesity drugs have produced that much weight loss in a mid-stage trial.
Eli Lilly is now running the Phase 3 TRIUMPH program, which will decide whether retatrutide eventually reaches the market.
AOD9604 vs Retatrutide: Side-by-Side Comparison
The table below summarizes the practical differences. These two compounds are not really competitors, since they belong to different drug classes and different eras of obesity research.
| Feature | AOD9604 | Retatrutide |
|---|---|---|
| Drug class | Growth hormone fragment (lipolytic peptide) | Triple GLP-1 / GIP / glucagon agonist |
| How it works | Stimulates fat breakdown and blocks new fat storage | Cuts appetite, slows stomach emptying, raises calorie burn |
| Administration | Subcutaneous injection; oral forms studied | Subcutaneous injection |
| Dosing in research | 250–500 mcg per day (grey-market protocols) | 1–12 mg once weekly, titrated upward |
| Development stage | Phase 2 completed; program discontinued | Phase 3 trials ongoing |
| Reported weight loss | Modest — a few pounds in small trials | Up to about 24% of body weight at 48 weeks (12 mg) |
| FDA status | Not approved for any human use | Not approved; investigational only |
| Common side effects | Injection-site reactions, headache | Nausea, vomiting, diarrhea, constipation, faster resting heart rate |
Why the Weight-Loss Results Are So Different
The gap in effectiveness comes down to how each compound works.
AOD9604 acts locally on fat cells, so its effect is limited by how much fat tissue it reaches and how strongly those cells respond. Human trials never showed the kind of large, sustained weight loss that regulators expect from a modern obesity drug.
Retatrutide changes whole-body energy balance. GLP-1 and GIP reduce hunger and slow digestion, while glucagon receptor activation appears to raise energy expenditure. The combination produced double-digit percentage weight loss in a matter of months.
That does not make AOD9604 useless as a research molecule. It simply means the two are not in the same category when results are measured on a scale.
Safety and Side Effects
Both compounds carry real uncertainty, though for different reasons.
- AOD9604: Human safety data is thin and dated. Marketers often call it side-effect free, but that claim rests on small, short studies rather than long-term monitoring.
- Retatrutide: Gastrointestinal side effects are common and dose-dependent. Trial participants also showed modest increases in resting heart rate, and the GLP-1 drug class overall has been linked to gallbladder problems and pancreatitis.
- Both: Long-term safety, drug interactions, and effects during pregnancy are unknown.
Anyone considering either compound should speak with a licensed healthcare professional first. Self-dosing with peptides bought from unverified vendors adds risks that have nothing to do with the molecule itself, including contamination, incorrect dosing, and no quality control.
How Retatrutide Compares With Other Weight-Loss Options
Most people researching retatrutide are trying to place it against drugs they already know. Semaglutide (Wegovy) and tirzepatide (Zepbound) are the approved options, and a comparison of retatrutide vs tirzepatide vs semaglutide usually comes down to average weight loss: roughly 15% for semaglutide, about 21% for tirzepatide, and around 24% for retatrutide at its highest trial dose. Those numbers come from separate trials, not head-to-head studies, so they are guideposts rather than proof that one drug is better.
Other investigational drugs are moving through trials too. If you are looking at cagrilintide vs retatrutide, the key difference is mechanism, because cagrilintide targets amylin receptors instead of incretin hormones. In the same way, a survodutide vs retatrutide comparison sets a dual GLP-1/glucagon agonist against retatrutide's triple action. Earlier-stage research chemicals such as SLU-PP-332 also enter the discussion, and a slu-pp-332 vs retatrutide search usually reflects curiosity about compounds that have never been tested in large human trials.
People also want a practical answer to aod 9604 vs retatrutide. The honest version is that one has modern Phase 3 data and the other does not, and that difference matters far more than any marketing claim.
Legal Status in the United States
Neither AOD9604 nor retatrutide can be legally prescribed in the US today.
AOD9604 has never received FDA approval, so products labeled AOD9604 are sold as research chemicals "not for human consumption." Retatrutide remains an investigational new drug, which means the only legitimate way to obtain it is by enrolling in a clinical trial.
Both substances fall under WADA's S0 category for non-approved pharmacological substances, which makes them prohibited for athletes at all times.
Buying either peptide from an online vendor for personal use is a grey area at best. The FDA has repeatedly warned that unapproved peptides sold online may be mislabeled, underdosed, or contaminated.
The Bottom Line
AOD9604 and retatrutide are separated by far more than a few pounds on a scale. Retatrutide is a Phase 3 triple agonist with weight-loss results that rival bariatric surgery, while AOD9604 is a discontinued growth hormone fragment with modest trial results and almost no modern data.
Neither is FDA-approved for human use in the United States. Anyone considering weight-loss treatment should talk with a physician about approved options such as semaglutide and tirzepatide before exploring unapproved peptides.
Frequently Asked Questions
Is AOD9604 or retatrutide FDA-approved?
Neither compound is FDA-approved for human use. Retatrutide is still an investigational drug being studied in Phase 3 clinical trials, and AOD9604 has never completed the approval process for any indication. Any product sold online as AOD9604 or retatrutide is not an approved medication.
Which works better for weight loss, AOD9604 or retatrutide?
Retatrutide has produced far greater weight loss in clinical trials. In its Phase 2 study, participants on the highest dose lost about 24% of their body weight over 48 weeks, while AOD9604 trials showed only modest reductions. The two have never been compared directly in a head-to-head trial.
Can you legally buy AOD9604 or retatrutide in the US?
Not as a consumer medication. Retatrutide is only available through enrollment in a clinical trial, and AOD9604 is not approved for any human use. Peptides sold online are marketed as research chemicals and are not intended for human consumption.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.